ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TNXP vs PLYX // RSI-14 & 200D SMA MOMENTUM

Tonix Pharmaceuticals Holding Corp. (NASDAQ) VS. Polaryx Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TNXP 1 — PLYX 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PLYX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNXP VS. PLYX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TNXP PLYX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 49.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -4.25% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 29.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 TNXP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 17.4 31.5 -14.08 PLYX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $90.6M $92.7M -$2.2M PLYX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TNXP REV PLYX REV TNXP GROSS % PLYX GROSS % TNXP FCF PLYX FCF
FY 2025 $13.1M $0 49.3% — -$103.2M -$3.9M
FY 2024 $10.1M $0 23.1% — -$61.0M -$2.6M
FY 2023 $7.8M — — — -$102.0M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNXP // BETA —
PLYX // BETA —